Effect of vasoactive peptides on prostacyclin synthesis in man.
Bradykinin, angiotensin II, arginine vasopressin (AVP) or des-amino-D-arginine vasopressin (DDAVP) were administered by intravenous infusion to 10 healthy men. The concentration of 6-oxo-prostaglandin F1 alpha (6-oxo-PGF1 alpha), the stable hydrolysis product of prostacyclin (PGI2), was measured in plasma using gas chromatography/negative ion chemical ionisation mass spectrometry. Dose-related increases in plasma concentrations of 6-oxo-PGF1 alpha occurred during administration of bradykinin (100-3200 ng kg-1 min-1). The concentrations of 6-oxo-PGF1 alpha rose from baseline values in the range less than 1.0-4.9 pg ml-1 to 24.9-47.6 pg ml-1 at maximum tolerated infusion rates. There were no changes in the concentrations of 6-oxo-PGF1 alpha during administration of angiotensin II, AVP or DDAVP at infusion rates which caused haemodynamic changes.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D000804:Angiotensin II / Q000494:pharmacology*; D001127:Arginine Vasopressin / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000494:pharmacology*; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology*; D011464:Epoprostenol / Q000096:biosynthesis*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male
D000804:Angiotensin II; D001127:Arginine Vasopressin; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D003894:Deamino Arginine Vasopressin; D001920:Bradykinin